Home › Funds › HSG Holding Ltd › LYEL
HSG Holding Ltd position in LYEL
LYELL IMMUNOPHARMA INC · Health Care
HSG Holding Ltd reported holding 152,299 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.12% of its reported portfolio and ranking #17 among its reported holdings. HSG Holding Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How HSG Holding Ltd's LYEL position evolved
HSG Holding Ltd first disclosed a stake in LYEL in Q3 2023 at 3,045,997 shares (US$4.5M). The position peaked in Q1 2024 at 3,045,997 shares, worth US$7.4M. Across 13 filings, HSG Holding Ltd increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 152,299 shares valued at US$1.5M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.05M | $4.48M | New |
| Q4 2023 | 3.05M | $6.40M | Hold |
| Q1 2024 | 3.05M | $7.43M | Hold |
| Q2 2024 | 3.05M | $5.00M | Hold |
| Q3 2024 | 3.05M | $3.41M | Hold |
| Q4 2024 | 3.05M | $1.74M | Hold |
| Q1 2025 | 3.05M | $1.46M | Hold |
| Q2 2025 | 152.30K | $1.35M | Reduce |
| Q3 2025 | 152.30K | $73.10K | Hold |
| Q4 2025 | 152.30K | $3.94M | Hold |
| Q1 2026 | 152.30K | $73.10K | Hold |
| Q2 2026 | 152.30K | $2.14M | Hold |
| Q3 2026 | 152.30K | $1.49M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LYEL and 13F data
LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 28 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LYEL
- ARCH Venture Management, LLC 3.25M sh · $45.53M · Q2 2026
- GSK plc 1.51M sh · $14.81M · Q3 2026
- Decheng Capital LLC 692.05K sh · $9.72M · Q2 2026
- Almitas Capital LLC 581.41K sh · $8.17M · Q2 2026
- Orland Properties Ltd 754.70K sh · $7.39M · Q3 2026
- Foresite Capital Management V, LLC 476.39K sh · $6.69M · Q2 2026
- Opaleye Management Inc. 344.02K sh · $4.83M · Q2 2026
- venBio Partners LLC 337.70K sh · $4.74M · Q2 2026
- Alphabet Inc. 293.26K sh · $2.87M · Q3 2026
- Velan Capital Investment Management LP 105.00K sh · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K sh · $1.22M · Q2 2026
More on HSG Holding Ltd
FAQ
How long has HSG Holding Ltd held LYEL?
HSG Holding Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is HSG Holding Ltd's current position in LYEL?
As of Q3 2026, HSG Holding Ltd holds 152.30K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $1.49M, representing 0.12% of its reported portfolio and ranking #17.
Has HSG Holding Ltd been buying or selling LYEL?
In the latest 13F filing (Q3 2026), HSG Holding Ltd held unchanged its position in LYEL. The position peaked in Q1 2024 at 3.05M shares.
Which other funds hold LYEL?
Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Decheng Capital LLC, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.